Correction: Discovery and clinical introduction of first-in-class imipridone ONC201

Joshua E. Allen¹, C. Leah B. Kline², Varun V. Prabhu¹, Jessica Wagner², Jo Ishizawa³, Neel Madhukar⁴, Avital Lev², Marie Baumeister², Lanlan Zhou², Amriti Lulla², Martin Stogniew¹, Lee Schalop¹, Cyril Benes^5,6, Howard L. Kaufman⁷, Richard S. Pottorf⁸, B. Rao Nallaganchu⁸, Gary L. Olson⁸, Fahd Al-Mulla⁹, Madeleine Duvic³, Gen Sheng Wu¹⁰, David T. Dicker², Mala K. Talekar¹¹, Bora Lim³, Olivier Elemento⁴, Wolfgang Oster¹, Joseph Bertino⁷, Keith Flaherty^5,6, Michael L. Wang³, Gautam Borthakur³, Michael Andreeff³, Mark Stein⁷ and Wafik S. El-Deiry²

¹ Oncoceutics, Inc., Philadelphia, PA, USA
² Fox Chase Cancer Center, Philadelphia, PA, USA
³ University of Texas MD Anderson Cancer Center, Houston, TX, USA
⁴ Weill Cornell Medicine, New York, NY, USA
⁶ Harvard Medical School, Boston, MA, USA
⁷ Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
⁸ Provid Pharmaceuticals, Monmouth Junction, NJ, USA
⁹ Kuwait University Medical School, Kuwait
¹⁰ Karmanos Cancer Institute, Detroit, MI, USA
¹¹ The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

Published: October 12, 2021

This article has been corrected: The COI statement has been updated. Please see the revised text below:

CONFLICTS OF INTEREST

W.S.E-D. is a co-founder and shareholder of Oncoceutics, Inc. W.S.E-D. is fully compliant with institutional disclosure requirements and conflict of interest rules. Dr. Michael Andreeff is also a shareholder of Oncoceutics, Inc. Some of the additional authors are employees or shareholders at Oncoceutics, Inc.

Original article: Oncotarget. 2016; 7:74380–74392. DOI: https://doi.org/10.18632/oncotarget.11814